Clinical Trials Logo

Enthesitis Related Arthritis clinical trials

View clinical trials related to Enthesitis Related Arthritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04527380 Active, not recruiting - Clinical trials for Juvenile Psoriatic Arthritis

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Start date: April 13, 2021
Phase: Phase 3
Study type: Interventional

The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) and juvenile psoriatic arthritis (JPsA).

NCT ID: NCT03858504 Completed - Clinical trials for Enthesitis Related Arthritis

Yoga Versus Home Exercise Program in Children With Enthesitis Related Arthritis

Start date: July 31, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effectiveness of different exercises programs as 'Yoga' and 'Home Exercise' in Enthesitis Related Arthritis.

NCT ID: NCT03769168 Active, not recruiting - Clinical trials for Juvenile Psoriatic Arthritis

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Start date: June 7, 2019
Phase: Phase 3
Study type: Interventional

Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).

NCT ID: NCT03031782 Completed - Clinical trials for Juvenile Psoriatic Arthritis

Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

Start date: May 23, 2017
Phase: Phase 3
Study type: Interventional

This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA). The study was divided into 3 parts (plus a post-treatment follow-up period) consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment Period 2